Biomarkers of Systemic Inflammation in Assessing the Efficacy of Extracorporeal Hemocorrection in the Treatment of Abdominal Sepsis
Open Access
- 10 May 2026
- journal article
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 15 (1) , 59-74
Abstract
Introduction Biomarkers such as procalcitonin (PCT), C-reactive protein (CRP), presepsin (PSP), and interleukin-6 (IL-6) are closely associated with systemic inflammation. The results of their testing were analyzed to determine the benefits of early use of extracorporeal hemocorrection (ECHC) in the treatment of abdominal sepsis. The Aim of the study was to analyze the results of simultaneous testing of PCT, CRP, PSP, and IL-6 biomarkers; to investigate the association between initial blood biomarker levels and disease outcome; to determine whether this relationship differed when using ECHC in the treatment of abdominal sepsis. Hypothesis tested the early use of ECHC in the treatment of abdominal sepsis has a survival advantage. Study design prospective cohor Material and methods Method description. Blood samples were taken at two time points — on the first postoperative day and after 5 days of intensive care — to determine systemic inflammation biomarkers. We analyzed the association between initial blood biomarker levels and outcome, as well as their dynamics after 5 days of intensive care. Sample characteristics . The study included 113 patients aged 23 to 90 years who underwent emergency laparotomy due to disseminated peritonitis and abdominal sepsis. The gender distribution was 67 men and 46 women. In 50 cases (group 1), ECHC was performed early; in 63 cases (group 2), ECHC was not used. Results Baseline PCT and PSP levels were statistically significantly and strongly associated with disease outcome; the relationship was direct for a negative outcome and inverse for a positive one. For each unit (mcg/ml) of PCT, the chance of survival decreased by 0.016 times (OR=0.984; 95% CI 0.974–0.994) and by 25.7 times over the entire range of values (OR=0.0389; 95% CI 0.0049–0.3050). For each unit (pg/mL) of PSP, the odds of a favorable outcome decreased by 1.00046 times (OR=0.99954; 95% CI 0.99919–0.99988) and by 117.6 times across the entire range (OR=0.0085; 95% CI 0.0002–0.2982). AUC 0.762; 95% CI 0.670–0.855 and 0.776; 95% CI 0.682–0.870. Early use of ECHC increased survival in patients with high baseline PCT and PSP levels. With standard sepsis therapy, the chances of survival were 1.040 times lower for each unit of PCT and 1.0006 times lower for each unit of PSP; 2387 times lower across the range of PCT values and 1.5 times lower across the range of PSP values compared to the use of ECHC in treatment. The use of ECHC allowed the survival of patients with higher initial levels of PCT (Me 29.4 (11.0–71.4) ng/ml versus Me 4.9 (2.1–10.5) ng/ml, p=0.000001) and PSP (Me 891 (504; 1686) pg/ml versus 386 (200; 848), p=0.007) compared to patients in whose treatment ECHC was not used. Unlike PCT, CRP, and IL-6, elevated PSP levels did not decrease with ECHC (p=0.38), while with standard sepsis therapy, the decrease was statistically significant (pConclusion Of the four biomarkers tested, procalcitonin best predicted the effectiveness of extracorporeal hemocorrection in the treatment of abdominal sepsis. The study revealed an unusual effect of extracorporeal hemocorrection on presepsin. A highly statistically significant positive association was observed between interleukin-6 and procalcitonin, presepsin, C-reactive protein, and APACHE II and SOFA scores after treatment with extracorporeal hemocorrection.Keywords
This publication has 27 references indexed in Scilit:
- Interleukin-6: obstacles to targeting a complex cytokine in critical illnessThe Lancet Respiratory Medicine, 2021
- The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cellsImmunity, 2021
- Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adultsCochrane Database of Systematic Reviews, 2019
- Presepsin: A promising biomarker for the detection of bacterial infectionsBiomedicine & Pharmacotherapy, 2019
- The diagnostic accuracy of procalcitonin and C‐reactive protein for sepsis: A systematic review and meta‐analysisJournal of Cellular Biochemistry, 2018
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trialIntensive Care Medicine, 2014
- Severe Sepsis and Septic ShockNew England Journal of Medicine, 2013
- Sepsis: molecular mechanisms underlying lipopolysaccharide recognitionExpert Reviews in Molecular Medicine, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987